• 1. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 2. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 3. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives

Methyl 4-bromo-3-formyl-1H-indazole-6-carboxylate (CAS No. 885518-48-9): A Versatile Intermediate in Modern Pharmaceutical Synthesis

Methyl 4-bromo-3-formyl-1H-indazole-6-carboxylate (CAS No. 885518-48-9) is a highly valuable intermediate in the field of pharmaceutical synthesis, playing a pivotal role in the development of novel therapeutic agents. This compound, characterized by its brominated and formyl functional groups, offers a unique scaffold for further chemical modifications, making it an attractive building block for medicinal chemists.

The structural features of Methyl 4-bromo-3-formyl-1H-indazole-6-carboxylate are particularly noteworthy. The presence of a bromine atom at the 4-position and a formyl group at the 3-position provides multiple points for selective functionalization. This allows for the introduction of diverse pharmacophores, enabling the synthesis of a wide range of derivatives with tailored biological activities. Such flexibility is crucial in drug discovery, where the optimization of molecular structure is essential for achieving desired pharmacokinetic and pharmacodynamic properties.

In recent years, there has been significant interest in indazole derivatives due to their broad spectrum of biological activities. These compounds have been investigated for their potential in treating various diseases, including cancer, infectious diseases, and neurological disorders. The formyl group in Methyl 4-bromo-3-formyl-1H-indazole-6-carboxylate serves as a key reactive site for condensation reactions, allowing for the formation of heterocyclic structures that are often associated with enhanced biological activity.

One of the most compelling applications of this compound is in the synthesis of kinase inhibitors. Kinases are enzymes that play a critical role in cell signaling pathways, and their dysregulation is often associated with various diseases, particularly cancer. By modifying the indazole core with appropriate substituents, researchers can develop inhibitors that selectively target specific kinases, thereby disrupting aberrant signaling pathways. The bromine atom in Methyl 4-bromo-3-formyl-1H-indazole-6-carboxylate facilitates cross-coupling reactions, such as Suzuki or Buchwald-Hartwig couplings, which are commonly employed in the construction of complex kinase inhibitors.

The pharmaceutical industry has increasingly recognized the importance of intermediates like Methyl 4-bromo-3-formyl-1H-indazole-6-carboxylate in accelerating drug development pipelines. The ability to rapidly synthesize and modify these intermediates allows for faster screening of potential drug candidates, reducing the time and cost associated with bringing new therapies to market. This efficiency is particularly valuable in an era where drug discovery faces numerous challenges, including increasing complexity of biological targets and stringent regulatory requirements.

Recent advances in synthetic methodologies have further enhanced the utility of Methyl 4-bromo-3-formyl-1H-indazole-6-carboxylate. For instance, flow chemistry techniques have enabled more controlled and scalable reactions, improving yields and purity levels. Additionally, green chemistry principles have been integrated into synthetic protocols to minimize waste and reduce environmental impact. These innovations not only streamline the production process but also align with global efforts to promote sustainable pharmaceutical manufacturing.

The versatility of Methyl 4-bromo-3-formyl-1H-indazole-6-carboxylate extends beyond kinase inhibitors. It has also been explored as a precursor for developing antimicrobial agents. The indazole scaffold is known to exhibit broad-spectrum antimicrobial activity, and modifications to this core structure can enhance efficacy against resistant strains of bacteria and fungi. The formyl group provides a convenient handle for further derivatization, allowing chemists to introduce functionalities that improve antimicrobial properties while maintaining solubility and bioavailability.

In conclusion, Methyl 4-bromo-3-formyl-1H-indazole-6-carboxylate (CAS No. 885518-48-9) represents a critical intermediate in modern pharmaceutical synthesis. Its unique structural features and reactivity make it an indispensable tool for medicinal chemists seeking to develop novel therapeutic agents. As research continues to uncover new applications for indazole derivatives, the demand for high-quality intermediates like this compound is expected to grow, driving further innovation in drug discovery and development.

• 885523-37-5(4-Bromo-3-formyl-1H-indazole-6-carboxylic acid)
• 885518-67-2(Methyl 6-bromo-3-cyano-1H-indazole-4-carboxylate)
• 885518-85-4(Methyl 6-bromo-3-formyl-1H-indazole-4-carboxylate)
• 433728-79-1(Methyl 3-formyl-1H-indazole-4-carboxylate)
• 78155-74-5(Methyl 5-bromo-1H-indazole-3-carboxylate)
• 885518-49-0(Methyl 6-bromo-1H-indazole-4-carboxylate)
• 885272-94-6(Ethyl 6-bromo-1H-indazole-3-carboxylate)
• 885278-42-2(Methyl 6-bromo-1H-indazole-3-carboxylate)
• 885518-47-8(Methyl 4-bromo-1H-indazole-6-carboxylate)
• 1190322-47-4(Methyl 4-bromo-1H-indazole-3-carboxylate)